IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Shares Outstanding (Basic Average) : 23.75 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. IPI Legacy Liquidation Co's average basic shares outstanding for the quarter that ended in Sep. 2023 was 23.75 Mil.

IPI Legacy Liquidation Co Shares Outstanding (Basic Average) Historical Data

The historical data trend for IPI Legacy Liquidation Co's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Shares Outstanding (Basic Average) Chart

IPI Legacy Liquidation Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Shares Outstanding (Basic Average)

13.14

14.60

23.45

IPI Legacy Liquidation Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Shares Outstanding (Basic Average)	Get a 7-Day Free Trial											23.71	23.74	23.75	23.75	23.75

IPI Legacy Liquidation Co Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

IPI Legacy Liquidation Co (OTCPK:IMPLQ) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

IPI Legacy Liquidation Co Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Shares Outstanding (Basic Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119

Website

https://www.impelpharma.com

Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Executives

Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb	officer: CFO	24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin	officer: VP, Controller & Interim CFO	C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson	director	1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams	director, officer: COB, CEO and President	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp	10 percent owner	525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019